{"id":43911,"date":"2021-01-05T08:30:52","date_gmt":"2021-01-05T13:30:52","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=43911"},"modified":"2021-01-05T02:35:30","modified_gmt":"2021-01-05T07:35:30","slug":"seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911","title":{"rendered":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial"},"content":{"rendered":"<p><strong>Seelos Therapeutics Inc. (NASDAQ:SEEL)<\/strong> has announced that its Phase IIb\/III SLS-005 (trehalose) study has been selected by Sean M. Healey &amp; AMG Centre for ALS at Massachusetts General Hospital to be part of <a href=\"https:\/\/www.prnewswire.com\/news-releases\/seelos-therapeutics-announces-the-selection-of-sls-005-trehalose-for-the-healey-als-platform-trial-for-amyotrophic-lateral-sclerosis-led-by-the-harvard-medical-school-301192478.html\" target=\"_blank\" rel=\"noopener noreferrer\">the HEALEY ALS platform Study<\/a>. This is the first-ever study platform for amyotrophic lateral sclerosis (ALS or Lou Gehrig&#8217;s disease) treatment.<\/p>\n<p><strong>SLS-005 included in HEALEY ALS Platform Trial <\/strong><\/p>\n<p>Raj Mehra, the company\u2019s CEO, stated that the inclusion of Seelos\u2019s registrational phase IIb\/III SLS-005 study in the first-ever platform trial is a huge milestone. It is a result of considerable work done in the identification of trehalose as a possible treatment to evaluate in ALS. He added that the recognition from the Healey\u2019s Centres of the therapy is a huge validation for the company and being part of the platform trial will help accelerate the trial by offering enhanced access to patients.<\/p>\n<p>Principal HEALEY ALS Platform Trial Investigator, Merit Cudkowicz said that they are delighted to work with Seelos. Merit said that they are looking forward to working with Seelos to study SLS-005 in expedited format via the HEALEY ALS platform. The trial design team is expected to work closely with the company on their regimen specific protocol and completion of necessary steps with the FDA\u2019s and central ethics review board.<\/p>\n<p><strong>HEALEY ALS Platform Trial enabling the simultaneous study of ALS therapies <\/strong><\/p>\n<p>It is important to note that the HEALEY ALS Platform Trial has been designed to <a href=\"https:\/\/finance.yahoo.com\/news\/seelos-therapeutics-announces-selection-sls-140000705.html\" target=\"_blank\" rel=\"noopener noreferrer\">evaluate potential ALS treatments<\/a> simultaneously thus accelerating potential treatment timing from identification through testing. Most importantly the platform trial model which has been successful in oncology aims to expedite multiple therapies studies this giving investigators a chance to test more possible therapies, reduce costs, shorten development timelines and increase patient access.<\/p>\n<p>The FDA recently granted SLS-005 Orphan Drug Designation for ALS treatment. SLS-005 is a molecular disaccharide that can cross the blood-brain barrier to stabilize and activate autophagy, the process which releases materials from cells. It activates autophagy through Transcription Factor EB activation which is a vital factor in autophagy gene expression.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced that its Phase IIb\/III SLS-005 (trehalose) study has been selected by Sean M. Healey &amp; AMG Centre for ALS [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":43710,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[14892,14891,14890],"stock_ticker":[14889],"class_list":["post-43911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqseel","tag-seelos-therapeutics-inc","tag-seelos-therapeutics-inc-nasdaqseel","stock_ticker-seel","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced that its Phase IIb\/III SLS-005 (trehalose) study has been selected by Sean M. Healey &amp; AMG Centre for ALS [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:30:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial\",\"datePublished\":\"2021-01-05T13:30:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\"},\"wordCount\":364,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg\",\"keywords\":[\"NASDAQ:SEEL\",\"Seelos Therapeutics Inc.\",\"Seelos Therapeutics Inc. (NASDAQ:SEEL)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\",\"name\":\"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg\",\"datePublished\":\"2021-01-05T13:30:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg\",\"width\":1200,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911","og_locale":"en_US","og_type":"article","og_title":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR","og_description":"Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced that its Phase IIb\/III SLS-005 (trehalose) study has been selected by Sean M. Healey &amp; AMG Centre for ALS [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2021-01-05T13:30:52+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial","datePublished":"2021-01-05T13:30:52+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911"},"wordCount":364,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg","keywords":["NASDAQ:SEEL","Seelos Therapeutics Inc.","Seelos Therapeutics Inc. (NASDAQ:SEEL)"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911","url":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911","name":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg","datePublished":"2021-01-05T13:30:52+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/10\/will-novavax-stock-rally-covid-19.jpg","width":1200,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/seelos-therapeutics-inc-nasdaqseel-announce-inclusion-of-sls-005-study-in-the-healey-als-platform-trial-43911#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Inclusion Of SLS-005 Study In The HEALEY ALS Platform Trial"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=43911"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/43911\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/43710"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=43911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=43911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=43911"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=43911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}